AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
AIM ImmunoTech completed dosing of the final subject in the Phase 2 DURIPANC trial of Ampligen combined with AstraZeneca’s Imfinzi for metastatic pancreatic cancer, reaching this milestone ahead of schedule. Topline results for the primary Clinical Benefit Rate endpoint are now anticipated in Q1 2027, with analysis of the Overall Survival endpoint expected to begin in June 2027.
Key figures
- Drug Name
- Ampligen (rintatolimod)
- Phase Of Trial
- Phase 2
- Primary endpoint
- Clinical Benefit Rate (CBR) at 24 weeks
- Os improvement months
- 22.3
- Biomarker subset criteria
- Neutrophil/Lymphocyte ratios less than 4.5
- Median os months npp subset
- 34.8
- Median os months historical control
- 12.5
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.